We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

USPTO To Reexamine Lipitor Patent

Law360 (December 8, 2004, 12:00 AM EST) -- In a troubling development for Pfizer Inc., the U.S. Patent and Trademark Office has agreed to reexamine the drug maker’s patent on the cholesterol-lowering treatment Lipitor, the world’s best-selling drug.

The USPTO issued its order based on a request by a small activist group, the Public Patent Foundation (PUBPAT), stating that the request raised "a substantial new question of patentability" regarding all 44 claims of the patent.

PUBPAT claims that the patent in question, issued in 1999 for a crystalline form of the drug, should be...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.